Continuing Education

ESHOS 2022 Annual Conference

Friday, November 18

Agenda

8:00 AM
Welcome and Assessment Introductions
Rahul Seth, DO
President, Empire State Hematology & Oncology Society

8:15 AM
Advances in the Treatment of Early-Stage Hormone Receptor Positive Breast Cancer
Yael Zack, MD
Medical Oncologist, White Plains Hospital

8:40 AM
Updates in Small Cell Lung Cancer
Abhirami Vivekanandarajah, MD
Medical Oncologist, New York Cancer & Blood Specialists

9:05 AM
Updates in Gastrointestinal Cancer
Joshua Raff, MD
Director of Digestive Cancer Program, White Plains Hospital

9:30 AM
Hematologic Malignancies
Joshua Brody, MD
Director of Lymphoma Immunotherapy Program, The Tish Cancer Institute at Mount Sinai

9:55 AM
Patient Selection for Novel Cellular Therapies
Joshua Brody, MD
Director of Lymphoma Immunotherapy Program, The Tish Cancer Institute at Mount Sinai

10:45 AM
Let's Get in Gear: Shifting from Low-Value to High-Value Care
Mark Liu, MHA
Director of Strategic Initiatives, Oncology, Mount Sinai Health System

11:05 AM
Clinician and Administrator Collaboration to Enhance Care Delivery
Mark Liu, MHA
Director of Strategic Initiatives, Oncology, Mount Sinai Health System

11:25 AM
Reimbursement for Diagnostic and Monitoring Tools
Jennifer Paquet, RN, BSN
Financial Assistance Patient Care Coordinator Supervisor, Bassett Cancer Institute

11:45 AM
Q&A and Assessment

12:00 PM
Lunch

1:00 PM
NYS Medicaid’s Attack on Oncology Physician Dispensing: An Update*
Jason Silberberg, Esq.
Frier Levitt

1:45 PM Enhancing Oncology Model*
Bo Gamble
Director of Quality and Value, Community Oncology Alliance

*CME/CNE not provided.

Learning Objectives

At the end of this educational activity, participants should be able to:

Review highlights of the advances in clinical and translational research presented at recent national clinical conferences.
Provide opportunities for discussion with leading oncology experts on translation of new investigational clinical and operational updates into patient care strategies.
Establish collaborations between community oncology clinicians and cancer program administrators to address challenges of integrating new data into practice.
Evaluate tools and resources in specific areas of cancer management that can be used to achieve effective cancer care delivery and improve the patient experience.

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This educational activity is supported by an educational grant from Daiichi Sankyo, Inc.

This educational activity is supported by an educational grant from GlaxoSmithKline.

Disclosure Information

Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Planners/Speakers

Name of Planner/Speaker	Reported Financial Relationship

Bianca Alvarez, MPH	No relevant financial relationships.
Bo Gamble	No relevant financial relationships.
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE	Jorge Garcia PharmD, MS, MHA, MBA, FACHE receives research funding from Pharmacosmos, is a speaker for ASHP, APhA, and MEC; is a consultant and on the Board of Trustees for FLASCO. He does not plan on discussing unlabeled/investigational uses of a commercial product
Regina Gibson- Burtnick, BBA, CAE	No relevant financial relationships.
Bo Gamble	No relevant financial relationships.
Gorge Garcia, PharmD, MS, MHA, MBA, FACHE	Jorge Garcia PharmD, MS, MHA, MBA, FACHE receives research funding from Pharmacosmos, is a speaker for ASHP, APhA, and MEC; is a consultant and on the Board of Trustees for FLASCO. He does not plan on discussing unlabeled/investigational uses of a commercial product
Lynette Henshaw, PharmD, CME Reviewer	No relevant financial relationships.
Christy Levine	No relevant financial relationships.
Mark Liu, MHA	No relevant financial relationships.
Matthew Manning, MD	Matthew Manning, MD, has equity stakes in Fuse Oncology. He does not plan on discussing unlabeled/investigational uses of a commercial product.
Sandra Megally	No relevant financial relationships.
Naomi Moeller, Boston University School of Medicine CME/CNE Office	No relevant financial relationships.
Jasmine Patel, PharmD, CME Reviewer	Jasmine Patel, PharmD, CME Reviewer is a speaker for AbbVie and was on the Myovant Ad Board.
Jennifer Paquet, RN, BSN	No relevant financial relationships.
Joshua Raff, MD	Joshua Raff, MD, has no relevant financial relationships. He plans to discuss unlabeled/investigational uses of a commercial product.
Amy Smith, CNE Course Advisor	No relevant financial relationships.
Sumanta Pal, MD	Sumanta Pal, MD, received honoraria for travel from CRISPR and Ipsen. He does not plan on discussing unlabeled/investigational uses of a commercial product.
Carmela A. Townsend, DNP, MS, MBA, RN, Lead Nurse Planner, Boston University School of Medicine CME/CNE Office	No relevant financial relationships.
Abhirami Vivekanandarajah, MD	Abhirami Vivekanandarajah, MD, is a speaker for AstraZeneca and consultant for Aptitude Health. She does not plan on discussing unlabeled/investigational uses of a commercial product.
Yael Zack, MD	No relevant financial relationships.
Wendi Waugh	No relevant financial relationships.

Accreditation Statement

Credit Designation for Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Empire State Hematology & Oncology Society (ESHOS).

Boston University School of Medicine designates this live activity for a maximum of 3.00 PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nurses

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity has been provided by Boston University School of Medicine Continuing Nursing Education and jointly provided by the Empire State Hematology & Oncology Society.

Contact Hours: 3.00, of which 3.00 is pharmacology credit worthy.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. Trustees of Boston University makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will trustees of Boston University be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care. In no event should information in the materials regarding laws, regulations, or legal liability be considered legal advice or used as a substitute for consulting with an attorney.